echo "datum här"; Isofol Strengthens Executive Management Team with the Appointment of Roger Tell, MD, PhD, as Chief Scientific Officer and Senior Vice President of Clinical Development | Isofol

Isofol Strengthens Executive Management Team with the Appointment of Roger Tell, MD, PhD, as Chief Scientific Officer and Senior Vice President of Clinical Development

GOTHENBURG, Sweden, November 19, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the recruitment of Roger Tell, MD., PhD as Chief Scientific Officer (CSO) and Senior Vice President (SVP) of clinical development. Dr. Tell has more than a decade of experience as a clinical oncologist in addition to holding management and advisory positions at Eli Lilly, AstraZeneca, Merck, Servier and Aprea Therapeutics. As the new chief scientific officer, Dr. Tell will be in charge of scientific research and technical operations at Isofol. Dr. Tell will also be involved in the strategy and developing of the clinical program for Isofol’s leading product candidate, arfolitixorin, now entering a global pivotal phase 3 clinical study.

Roger Tell, MD, PhD, Isofol’s chief scientific officer and senior vice president of clinical development said, “I am thrilled to join the Isofol team at such an exciting time for the company. The initiation of a global Phase 3 clinical study is a major milestone. I look forward to guiding this process and ensuring that we are diligently progressing the arfolitixorin program towards eventual commercialization so that we can help increase the effectiveness of chemotherapy for colorectal cancer, a condition with a great unmet need.”

“We are excited for the addition of Roger to the Isofol team,” added Anders Rabbe, chief executive officer of Isofol. “His addition helps solidify our management team with a CSO who has a strong background in medical oncology in addition to significant experience in the biopharma industry. We only stand to benefit from his guidance as we lay the groundwork for the global Phase 3 clinical trial for arfolitixorin and for our ongoing research and development initiatives in the future.”

Dr. Tell has extensive experience as a practicing physician in oncology as well as an advisor to a number of biopharma companies. He received his medical degree from the Karolinska Institute in 1998 followed by a doctorate of philosophy (Ph.D.) in oncology and experimental oncology in 2004, also from the Karolinska Institute. Following a residency in oncology he worked as a medical advisor in oncology for Eli Lilly in Sweden. He then served as the Nordic medical director of oncology, infection and vaccine for Astra Zeneca combining this position as assistant professor in the department of oncology-pathology at the Karolinska Institute. Dr. Tell then returned to the Karolinska University Hospital as a consultant for mainly thoracic malignancies and acted as the principal investigator of multiple Phase 1-3 trials.

Dr. Tell has also worked as a medical advisor for Merck and as a project director for the Institut de Recherches Internationales Servier (IRIS) in Paris. Dr. Tell currently holds the position as vice president of clinical development at Aprea Therapeutics and will initiate his role as Isofol’s chief scientific officer and senior vice president of clinical development on February 1, 2019.

For more information, please contact:

Isofol Medical AB (publ):
Anders Rabbe, CEO
E-mail: anders.rabbe@isofolmedical.com
Phone: +46 (0)707 646 500

Investor Relations:
Hans Herklots
LifeSci Advisors
E-mail: hherklots@lifesciadvisors.com
Phone: +41 79 598 7149

Media:
Alison Chen
LifeSci Public Relations
E-mail: achen@lifescipublicrelations.com
Phone: +1 646-876-4932

About arfolitixorin

Arfolitixorin is a new drug candidate developed to increase the efficacy of the cytotoxic agent 5‑fluorouracil (5-FU) and as a rescue drug after high-dose methotrexate treatment. Arfolitixorin, [6R]-5,10-methylene-tetrahydrofolate is the key active metabolite of the widely used folate-based drugs leucovorin and levoleucovorin. Arfolitixorin may be suitable for all patients regardless of their ability to activate folates to [6R]-5,10-methylenetetrahydrofolate, since arfolitixorin, unlike leucovorin and levoleucovorin, does not require metabolic activation to exert its effect.

About Isofol Medical AB (publ)

Isofol Medical AB (publ) is a biotech company within the field of oncology developing arfolitixorin, primarily as a treatment for advanced colorectal cancer and as a rescue drug after high-dose methotrexate treatment in osteosarcoma (bone cancer). Through a worldwide exclusive license agreement, Isofol holds the rights to develop and commercialise arfolitixorin within oncology with access to the unique patented production process and the production capabilities of Merck KGaA, Darmstadt, Germany. Isofol Medical AB is traded on the Nasdaq First North Premier. Certified Adviser is FNCA Sweden AB.

 

www.isofolmedical.com